Enzo Biochem's Q1 Revenues Rise 2 Percent | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Enzo Biochem today reported that its first-quarter 2011 revenues increased 2 percent as increased sales for its clinical labs business offset lower revenues for its life sciences unit.

The New York-based research products and testing firm brought in total revenues of $25.7 million for the three-month period ended Oct. 31, compared to revenues of $25.2 million for the first quarter of fiscal 2010.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.